Abstract
Medical treatment of cystoid macular edema (CME) with carbonic anhydrase inhibitors has been known for over a decade. Initial observations were based on experimental data which suggested that acetazolamide can increase fluid absorption across the retinal pigment epithelium. Carbonic anhydrase inhibitors (CAI) have also been shown to have other direct effects both on retinal and retinal pigment epithelial cell function by inducing an acidification of the subretinal space, a decrease of the standing potential as well as an increase in retinal adhesiveness. It is thought that acidification of the subretinal space is finally responsible for the increase in fluid resorption from the retina through the RPE into the choroid. Several clinical studies have suggested that patients with cystoid macular edema due to retinitis pigmentosa and uveitis may react more favorably to CAI treatment than other etiologies such as diabetic maculopathy or macular edema after retinal vein occlusion. The present working hypothesis is that diffuse leakage from the RPE responds more readily to CAI treatment than leakage from retinal vessels. This may be due to the modulation of membrane- bound CA IV in the RPE which may have lost its polarised distribution in the presence of macular edema. A normal clinical starting dose of CAI is 500 mg/day which should be continued for at least one month to see an effect. This dose may be reduced by the patients over the course of therapy. Metaphylaxis to the drug may occur with a rebound of the edema despite continuation of treatment.
Similar content being viewed by others
References
Becker B. Decrease in intraocular pressure in man by a carbonic anhydrase inhibitor. Am J Ophthalmol 1954; 37: 13-15.
Cox SN, Hay E, Bird AC. Treatment of chronic macular edema with acetazolamide Arch Ophthalmol 1988; 106: 190-1195.
Farber MD, Lam S, Tessler HH, Jennings TJ, Cross A, Rusin MM. Reduction of macular oedema by acetazolamide in patients with chronic iridocyclitis: a randomised prospective crossover study Br I Ophthalmol 1994; 78: 4-7.
Fishman GA, Gilbert LD, et al. Acetazolamide for treatment of chronic macular edema in retinitis pigmentosa Arch Ophthalmol 1989; 107: 1445-52.
Chen JC, Fitzke FW, Bird AC. Long-term effect of acetazolamide in a patient with retinitis pigmentosa Invest Ophthalmol Vis Sci 1990; 31: 1914-8.
Marmor MF. Hypothesis concerning carbonic anhydrase treatment of cystoid macular edema: example with epiretinal membrane. Arch Ophthalmol 1990; 108: 1524-5.
Lichter PR. Reducing side effects of carbonic anhydrase inhibitors Ophthalmology 1981; 88: 266-9.
Travis DM. Renal carbonic anhydrase inhibition by benzolamide (CL 11,366) in Man. J Pharmacol Exp Ther 1969; 167: 253-64.
Dodgson SJ. The carbonic anhydrases: overview of their importance in cellular physiology and in molecular genetics. In: Dodgson SJ, Tashian RE, Gros G, Carter ND, eds. The carbonic anhydrases: cellular physiology and molecular genetics., ed. New York: Plenum; 1991: 3-13.
Wistrand PJ, Schenholm M, Lonnerholm G Carbonic anhydrase isoenzymes C in the human eye Invest Ophthalmol Vis Sci 1986; 27: 419-28.
Wolfensberger TJ, Mahieu I, Jarvis-Evans J, Boulton M, Nogradi A, Hollande E, Carter ND, Bird AC. Membrane-bound carbonic anhydrase in human retinal pigment eptithelium. Invest Ophthalmol Vis Sci 1994; 35: 3401-7.
Mahieu I, Becq F, Wolfensberger TJ, Gola M, Carter N, Hollande E. The expression of carbonic anhydrases II and IV in the human pancreatic cancer cell line (CAPAN 1) is associated with bicarbonate ion channels Biol Cell 1994; 81: 131-41.
Travis DM, Wiley C, Nechan BR, Maren TH. Selective Renal Carbonic Anhydrase Inhibition without Respiratory Effect: Pharmacology of 2-benzenesulfonamido-1,3,4-thiadiazole 5-sulfonamide (CL 11,366). J Pharmacol Exp Ther 1964; 143: 383-94.
Wistrand PJ, Rawls JA, Maren TH. Sulphonamide carbonic anhydrase inhibitors and intra-ocular pressure in rabbits. Acta pharmacol toxicol 1960; 17: 337-355.
Broder LE, Oppelt WW. Effect of benzolamide on cerebrospinal fluid formation. J Pharmacol Exp Ther 1969; 169: 271-6.
Hanson MA, Nye PCG, Torrance RW. The location of carbonic anhydrase in relation to the blood-brain barrier at the medullary chemoreceptors of the cat. J Physiol 1981; 320: 113-25.
Johanson CE. Differential effects of acetazolamide, benzolamide and systemic scidosis on hydrogen and bicarbonate gradients across the apical and basolateral membranes of the choroid plexus. J Pharm Exp Ther 1984; 231: 502-11.
Saarikoski J, Kaila K. Simultaneous measurement of intracellular and extracellular carbonic anhydrase activity in intact muscle fibres. Pflugers Arch 1992; 421: 357-63.
Marmor MF, Negi A. Pharmacologic modification of subretinal fluid absorption in the rabbit eye. Arch Ophthalmol 1986; 104: 1674-7.
Negi A, Marmor MF. Quantitative estimation of metabolic transport of subretinal fluid. Invest Ophthalmol Vis Sci 1986; 27: 1564-8.
Frambach DA, Marmor MF. The rate and route of fluid resorption from the subretinal space of the rabbit. Invest Ophthalmol Vis Sci 1982; 22: 292-302.
Marmor MF, Maack T. Enhancement of retinal adhesion and subretinal fluid resorption by acetazolamide. Invest Ophthalmol Vis Sci 1982; 23: 121-4.
Marmor MF, Abdul-Rahim AS, Cohen DS. The effect of metabolic inhibitors on retinal adhesion and subretinal fluid resorption. Invest Ophthalmol Vis Sci 1980; 19: 893-903.
Wolfensberger TJ, Chiang R, Takeuchi A, Marmor MF. Inhibition of membranebound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness. Graefes Arch Clin Exp Ophthalmol 1999; in press
Tsuboi S, Pederson JE. Experimental retinal detachment. X. Effect of acetazolamide on vitreous fluorescein disappearance. Arch Ophthalmol 1985; 103: 1557-8.
Miller SS, Steinberg RH. Active transport of ions across frog retinal pigment epithelium. Exp Eye Res 1977; 25: 235.
Wolfensberger TJ, Dimitriev AV, Govardovskii VI, Steinberg RH. Inhibition of membrane-bound carbonic anhydrase decreases subretinal volume and pH. Invest Ophthalmol Vis Sci 1996; 37 suppl: S1109.
Yamamoto F, Steinberg RH. Effects of intravenous acetazolamide on retinal pH in the cat Exp Eye Res 1992; 54: 711-8.
Kawasaki K, Mukoh S, Yonemura D, et al. Acetazolamide-induced changes of the membrane potentials of the retinal pigment epithelial cell. Doc Ophthalmol 1986; 63: 375-81.
Cox SN, Weinstein G, Arden GB, Bird AC. The effect of acetazolamide on electrooculogram potential Invest Ophthalmol Vis Sci 1988; 29 (suppl): 146.
Marmor MF. Mechanisms of retinal adhesion Progr Retinal Research 1993; 12: 179-204.
Kita M, Marmor MF. Retinal adhesive force in living rabbit, cat and monkey eyes. Invest Ophthalmol Vis Sci 1992; 33: 1879-82.
Kita M, Marmor MF. Effects on retinal adhesive force in vivo of metabolically active agents in the subretinal space. Invest Ophthalmol Vis Sci 1992; 33: 1883-7.
Endo EG, Yao X-Y, Marmor MF. Pigment adherence as a measure of retinal adhesion: dependence on temperature. Invest Ophthalmol Vis Sci 1988; 29: 1390-6.
Fishman GA, Glenn AM, Gilbert LD. Rebound macular edema with continued use of methazolamide in patinets with retinitis pigmentosa. Arch Ophthalmol 1993; 111: 1640-6.
Schilling H, Heiligenhaus A, Pauleikhoff D, Wessing A. Long-time results of treating chronic cystoid macular edema with low-dose acetazolamide in patients with uveitis and pseudophakia. Invest Ophthalmol Vis Sci 1995; 36 suppl.: S777.
Whitcup SM, Csaky KG, Podgor MJ, Chew EY, Perry CH, Nussenblatt RB. A randomized, masked, cross-over trial of acetazolamide for cystoid macular edema in patients with uveitis. Ophthalmology 1996; 103: 1054-62.
Wolfensberger TJ, Godley B, Downes S, Holz FG, Fitzke FW, Bird AC. Treatment of cystoid macular edema with acetazolamide and benzolamide: a prospective double-blind placebo-controlled cross-over trial, Invest Ophthalmol Vis Sci 1997; 38: S4320.
Grover S, Fishman GA, Fiscella RG, Adelman AE. Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Retina 1997; 17: 222-31.
Newsome DA. Retinal fluorescein leakage in retinitIs pigmentosa. Am J Ophthalmol 1986; 101: 354-60.
Wehner F, Alexandridis E, Bettinger F. Elektrookulographische Befunde bei Uveitis Forschr Ophthalmol 1970; 70: 161-5.
Casswell AG, Chaine G, Rush P Paramacular teleangiectasis. Trans Ophthalmol Soc UK 1986; 105: 683-92.
Steinmetz RL, Fitzke FW, Bird AC. Treatment of cystoid macular edema with acetazolamide in a patient with serpiginous choroidopathy. Retina 1991; 11: 412-5.
Edelman JL, Lin H, Miller SS. Acidification stimulates chloride and fluid absorption across frog retinal pigment epithelium. Am J Physiol 1994; 266: C946-56.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wolfensberger, T.J. The role of carbonic anhydrase inhibitors in the management of macular edema. Doc Ophthalmol 97, 387–397 (1999). https://doi.org/10.1023/A:1002143802926
Issue Date:
DOI: https://doi.org/10.1023/A:1002143802926